Pharsight

1. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8847766	OTSUKA	Pharma-informatics system	Mar, 2030 (7 years from now)
US8545402	OTSUKA	Highly reliable ingestible event markers and methods for using the same	Apr, 2030 (7 years from now)
US8114021	OTSUKA	Body-associated receiver and method	Jun, 2030 (7 years from now)
US9941931	OTSUKA	System for supply chain management	Nov, 2030 (8 years from now)
US8961412	OTSUKA	In-body device with virtual dipole signal amplification	Nov, 2030 (8 years from now)
US8258962	OTSUKA	Multi-mode communication ingestible event markers and systems, and methods of using the same	Nov, 2030 (8 years from now)
US8547248	OTSUKA	Implantable zero-wire communications system	Dec, 2030 (8 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

2. Drug name - ACETAMINOPHEN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959	FRESENIUS KABI USA	Paracetamol for parenteral administration	Apr, 2030 (7 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
1GM/100ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

3. Drug name - AKYNZEO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (8 years from now)
US9943515	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (8 years from now)
US8951969	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (8 years from now)
US8623826	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (8 years from now)
US10828297	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Dec, 2030 (8 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
300MG;EQ 0.5MG BASE	CAPSULE;ORAL	Prescription

4. Drug name - AKYNZEO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Nov, 2030 (8 years from now)
US10828297	HELSINN HLTHCARE	Compositions and methods for treating centrally mediated nausea and vomiting	Dec, 2030 (8 years from now)

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

5. Drug name - ALECENSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922	HOFFMANN-LA ROCHE	Tetracyclic compound	Jun, 2030 (7 years from now)

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	CAPSULE;ORAL	Prescription

6. Drug name - ALUNBRIG

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462	TAKEDA PHARMS USA	Phosphorous derivatives as kinase inhibitors	Jul, 2030 (7 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

7. Drug name - AMONDYS 45

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9228187	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (8 years from now)
US10287586	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (8 years from now)
CN105838714A	SAREPTA THERAPS INC	Antisense Molecule And Method For Treating Disease.	Nov, 2030 (8 years from now)
CN105838714B	SAREPTA THERAPS INC	Antisense Molecules And Method For Treating Disease	Nov, 2030 (8 years from now)
IN347912B	SAREPTA THERAPS INC	Antisense Molecules And Methods For Treating Pathologies	Nov, 2030 (8 years from now)
IN201204202P4	SAREPTA THERAPS INC	Antisense Molecules And Methods For Treating Pathologies	Nov, 2030 (8 years from now)
EP2499249B1	SAREPTA THERAPS INC	Antisense Molecules And Methods For Treating Pathologies	Nov, 2030 (8 years from now)
EP2499249A4	SAREPTA THERAPS INC	Antisense Molecules And Methods For Treating Pathologies	Nov, 2030 (8 years from now)
EP2499249A1	SAREPTA THERAPS INC	Antisense Molecules And Methods For Treating Pathologies	Nov, 2030 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10781450	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (8 years from now)
US9758783	SAREPTA THERAPS INC	Antisense molecules and methods for treating pathologies	Nov, 2030 (8 years from now)

Drugs and Companies using CASIMERSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
100MG/2ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription

8. Drug name - AMZEEQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137200	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (8 years from now)
US8865139	JOURNEY	Topical tetracycline compositions	Oct, 2030 (8 years from now)
US9675700	JOURNEY	Topical tetracycline compositions	Oct, 2030 (8 years from now)
US8992896	JOURNEY	Topical tetracycline compositions	Oct, 2030 (8 years from now)
US10086080	JOURNEY	Topical tetracycline compositions	Oct, 2030 (8 years from now)
US10213512	JOURNEY	Topical tetracycline compositions	Oct, 2030 (8 years from now)
US10517882	JOURNEY	Method for healing of an infected acne lesion without scarring	Oct, 2030 (8 years from now)
US10821187	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (8 years from now)
US10265404	JOURNEY	Compositions, gels and foams with rheology modulators and uses thereof	Oct, 2030 (8 years from now)
US8945516	JOURNEY	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses	Oct, 2030 (8 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
EQ 4% BASE	AEROSOL, FOAM;TOPICAL	Prescription

9. Drug name - ANJESO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253478	BAUDAX	Reduction of flake-like aggregation in nanoparticulate active agent compositions	May, 2030 (7 years from now)
US9974746	BAUDAX	Reduction of flake-like aggregation in nanoparticulate active agent compositions	May, 2030 (7 years from now)
US10709713	BAUDAX	Nanoparticulate meloxicam formulations	May, 2030 (7 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
30MG/ML (30MG/ML)	SOLUTION;INTRAVENOUS	Prescription

10. Drug name - ANORO ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (8 years from now)
US11090294	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (8 years from now)
US9750726	GLAXOSMITHKLINE	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist	Nov, 2030 (8 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

11. Drug name - APADAZ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9132125	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)
US9549923	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof	Jul, 2030 (7 years from now)
US8748413	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)
CN102480959A	KVK TECH INC	Benzoic Acid Conjugate Of Hydrocodone, Benzoic Acid Derivative Conjugate, Heteroaryl Carboxylic Acid Conjugate And Predrug, Preparation Method And Usage Thereof	Jul, 2030 (7 years from now)
CN102480959B	KVK TECH INC	Benzoic Acid Conjugate Of Hydrocodone, Benzoic Acid Derivative Conjugate And Heteroaryl Carboxylic Acid Conjugates And Prodrugs Thereof, Preparation Method And Use Thereof	Jul, 2030 (7 years from now)
IN201110011P1	KVK TECH INC	Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof	Jul, 2030 (7 years from now)
IN293793B	KVK TECH INC	Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof	Jul, 2030 (7 years from now)
EP2448407B1	KVK TECH INC	Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof	Jul, 2030 (7 years from now)
EP2448407A1	KVK TECH INC	Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof	Jul, 2030 (7 years from now)
EP2448407A4	KVK TECH INC	Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978	KVK TECH INC	Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof	Jul, 2030 (7 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
325MG;EQ 4.08MG BASE	TABLET;ORAL	Prescription
325MG;EQ 6.12MG BASE	TABLET;ORAL	Prescription
325MG;EQ 8.16MG BASE	TABLET;ORAL	Prescription

12. Drug name - APRISO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688	VALEANT PHARMS INTL	Compositions and methods for treatment of bowel diseases with granulated mesalamine	May, 2030 (7 years from now)

Drugs and Companies using MESALAMINE ingredient

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
375MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

13. Drug name - APTIOM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372431	SUNOVION PHARMS INC	Pharmaceutical composition comprising licarbazepine acetate	Apr, 2030 (7 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
400MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription
800MG	TABLET;ORAL	Prescription

14. Drug name - ARISTADA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)
US8431576	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Oct, 2030 (8 years from now)
EP2445502B1	ALKERMES INC	Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders	Jun, 2030 (7 years from now)
EP2445502A1	ALKERMES INC	Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders	Jun, 2030 (7 years from now)
EP2445343A1	ALKERMES INC	Prodrugs Of Nh-Acidic Compounds	Jun, 2030 (7 years from now)
EP2445343B1	ALKERMES INC	Prodrugs Of Nh-Acidic Compounds	Jun, 2030 (7 years from now)
EP2445502A4	ALKERMES INC	Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders	Jun, 2030 (7 years from now)
EP2445343A4	ALKERMES INC	Prodrugs Of Nh-Acidic Compounds	Jun, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

15. Drug name - ARISTADA INITIO KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)
US8431576	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Oct, 2030 (8 years from now)
EP2445502B1	ALKERMES INC	Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders	Jun, 2030 (7 years from now)
EP2445502A1	ALKERMES INC	Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders	Jun, 2030 (7 years from now)
EP2445343A1	ALKERMES INC	Prodrugs Of Nh-Acidic Compounds	Jun, 2030 (7 years from now)
EP2445343B1	ALKERMES INC	Prodrugs Of Nh-Acidic Compounds	Jun, 2030 (7 years from now)
EP2445502A4	ALKERMES INC	Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders	Jun, 2030 (7 years from now)
EP2445343A4	ALKERMES INC	Prodrugs Of Nh-Acidic Compounds	Jun, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276	ALKERMES INC	Heterocyclic compounds for the treatment of neurological and psychological disorders	Jun, 2030 (7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
675MG/2.4ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

16. Drug name - ARNUITY ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXOSMITHKLINE	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXOSMITHKLINE	Medicament dispenser	Oct, 2030 (8 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.05MG/INH	POWDER;INHALATION	Prescription
0.1MG/INH	POWDER;INHALATION	Prescription
0.2MG/INH	POWDER;INHALATION	Prescription

17. Drug name - ATROVENT HFA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447	BOEHRINGER INGELHEIM	Inhaler device	Jan, 2030 (7 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.021MG/INH	AEROSOL, METERED;INHALATION	Prescription

18. Drug name - AUBAGIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735	SANOFI AVENTIS US	(Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability	Sep, 2030 (7 years from now)

Drugs and Companies using TERIFLUNOMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

19. Drug name - AURYXIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300039	KERYX BIOPHARMS	Ferric citrate dosage forms	Jul, 2030 (7 years from now)
US9387191	KERYX BIOPHARMS	Ferric citrate dosage forms	Jul, 2030 (7 years from now)

Drugs and Companies using FERRIC CITRATE ingredient

Treatment: Control of serum phosphorus levels

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 210MG IRON	TABLET;ORAL	Prescription

20. Drug name - AVYCAZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455	ALLERGAN	Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt	Oct, 2030 (8 years from now)

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.5GM BASE;2GM/VIAL	POWDER;INTRAVENOUS	Prescription

21. Drug name - BESIVANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8604020	BAUSCH AND LOMB	Fluoroquinolone carboxylic acid molecular crystals	Mar, 2030 (7 years from now)
US8415342	BAUSCH AND LOMB	Besifloxacin ophthalmic composition for the treatment or control of infection	Nov, 2030 (8 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.6% BASE	SUSPENSION/DROPS;OPHTHALMIC	Prescription

22. Drug name - BEVESPI AEROSPHERE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703806	ASTRAZENECA	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	May, 2030 (7 years from now)
US8808713	ASTRAZENECA	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US10716753	ASTRAZENECA	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US9463161	ASTRAZENECA	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	May, 2030 (7 years from now)
US9415009	ASTRAZENECA	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US8324266	ASTRAZENECA	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.0048MG/INH;0.0090MG/INH	AEROSOL, METERED;INHALATION	Prescription

23. Drug name - BEVYXXA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987463	PORTOLA PHARMS INC	Methods of synthesizing factor Xa inhibitors	Dec, 2030 (8 years from now)

Drugs and Companies using BETRIXABAN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
40MG	CAPSULE;ORAL	Discontinued
80MG	CAPSULE;ORAL	Discontinued

24. Drug name - BEYAZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597	BAYER HLTHCARE	Pharmaceutical composition containing a tetrahydrofolic acid	Feb, 2030 (7 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	TABLET;ORAL	Prescription

25. Drug name - BRAFTOVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541575	ARRAY BIOPHARMA INC	3,4-diarylpyrazoles as protein kinase inhibitors	Feb, 2030 (7 years from now)
US9593099	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
CN102725283A	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
CN103896921A	ARRAY BIOPHARMA INC	Compound And Composition As A Protein Kinase Inhibitor	Aug, 2030 (7 years from now)
CN102725283B	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
CN103896921B	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
IN201202469P1	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
IN303554B	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
EP2727918B1	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
EP2727918A1	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
EP2470526B1	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
EP2470526A1	ARRAY BIOPHARMA INC	Compounds And Compositions As Protein Kinase Inhibitors	Aug, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9593100	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9850229	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9850230	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US10005761	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued
75MG	CAPSULE;ORAL	Prescription

26. Drug name - BREO ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXO GRP LTD	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXO GRP LTD	Medicament dispenser	Oct, 2030 (8 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.1MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription
0.2MG/INH;EQ 0.025MG BASE/INH	POWDER;INHALATION	Prescription

27. Drug name - BREXAFEMME

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085	SCYNEXIS	Antifungal agents	Aug, 2030 (7 years from now)

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription

28. Drug name - BREZTRI AEROSPHERE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009	ASTRAZENECA AB	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US10716753	ASTRAZENECA AB	Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US8703806	ASTRAZENECA AB	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents	May, 2030 (7 years from now)
US8808713	ASTRAZENECA AB	Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems	May, 2030 (7 years from now)
US8324266	ASTRAZENECA AB	Compositions, methods and systems for respiratory delivery of two or more active agents	May, 2030 (7 years from now)
US9463161	ASTRAZENECA AB	Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems	May, 2030 (7 years from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

Strength	Dosage	Availability
0.16MG/INH;0.0048MG/INH;0.009MG/INH	AEROSOL, METERED;INHALATION	Prescription

29. Drug name - BRILINTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934	ASTRAZENECA	Pharmaceutical compositions	Apr, 2030 (7 years from now)

Drugs and Companies using TICAGRELOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription

30. Drug name - BRIVIACT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653	UCB INC	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives	Apr, 2030 (7 years from now)

Drugs and Companies using BRIVARACETAM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
75MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

31. Drug name - BYDUREON

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8998876	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jan, 2030 (7 years from now)
US8721615	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jan, 2030 (7 years from now)
US8998876 (Pediatric)	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jul, 2030 (7 years from now)
US8721615 (Pediatric)	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jul, 2030 (7 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued
2MG	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Discontinued

32. Drug name - BYDUREON BCISE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033	ASTRAZENECA AB	Sustained release formulations using non-aqueous carriers	Oct, 2030 (8 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.85ML (2MG/0.85ML)	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	Prescription

33. Drug name - CABOMETYX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan, 2030 (7 years from now)
US8877776	EXELIXIS INC	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct, 2030 (8 years from now)
EP2387563B2	EXELIXIS INC	Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer	Jan, 2030 (7 years from now)
EP2387563B1	EXELIXIS INC	Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer	Jan, 2030 (7 years from now)
EP2387563A1	EXELIXIS INC	Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer	Jan, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (7 years from now)
US11091440	EXELIXIS INC	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (7 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of renal cell carcinoma; treatment of advanced renal cell carcinoma; treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 60MG BASE	TABLET;ORAL	Prescription

34. Drug name - CALDOLOR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012508	CUMBERLAND PHARMS	Administration of intravenous ibuprofen	Sep, 2030 (7 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
400MG/4ML (100MG/ML)	SOLUTION;INTRAVENOUS	Discontinued
800MG/8ML (100MG/ML)	SOLUTION;INTRAVENOUS	Prescription
800MG/200ML (4MG/ML)	SOLUTION;INTRAVENOUS	Prescription

35. Drug name - CHILDREN'S ALLEGRA ALLERGY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933097	CHATTEM SANOFI	Fexofenadine suspension formulation	Aug, 2030 (7 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
30MG/5ML	SUSPENSION;ORAL	Discontinued

36. Drug name - COMBIVENT RESPIMAT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (8 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

Strength	Dosage	Availability
EQ 0.1MG BASE/INH;0.02MG/INH	SPRAY, METERED;INHALATION	Prescription

37. Drug name - COMETRIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan, 2030 (7 years from now)
US8877776	EXELIXIS	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct, 2030 (8 years from now)
EP2387563B2	EXELIXIS	Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer	Jan, 2030 (7 years from now)
EP2387563B1	EXELIXIS	Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer	Jan, 2030 (7 years from now)
EP2387563A1	EXELIXIS	Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer	Jan, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091440	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (7 years from now)
US11098015	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (7 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 80MG BASE	CAPSULE;ORAL	Prescription

38. Drug name - CONSENSI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408837	PURPLE BIOTECH	Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs	Feb, 2030 (7 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 2.5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 5MG BASE;200MG	TABLET;ORAL	Discontinued
EQ 10MG BASE;200MG	TABLET;ORAL	Discontinued

39. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8916195	NALPROPION	Sustained release formulation of naltrexone	Feb, 2030 (7 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

40. Drug name - COPIKTRA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182	SECURA	Substituted isoquinolin-1(2H)-ones, and methods of use thereof	Feb, 2030 (7 years from now)
CN102711767B	SECURA	Some Real Chemistry, Composition And Method	Jul, 2030 (7 years from now)
CN109912599A	SECURA	Chemical Entities, Compositions And Methods	Jul, 2030 (7 years from now)
CN109912599B	SECURA	Chemical Entities, Compositions And Methods	Jul, 2030 (7 years from now)
CN102711767A	SECURA	Certain Chemical Entities, Compositions And Method	Jul, 2030 (7 years from now)
CN106188059A	SECURA	Some Real Chemistry, Composition And Method	Jul, 2030 (7 years from now)
CN106188059B	SECURA	Certain Chemical Entities, Compositions And Method	Jul, 2030 (7 years from now)
IN201200943P1	SECURA	Certain Chemical Entities, Compositions And Methods	Jul, 2030 (7 years from now)
EP3150609A1	SECURA	Process For Preparing Certain Chemical Entities	Jul, 2030 (7 years from now)
EP2918589A1	SECURA	Adenine Derivative As Pi3K Inhibitor	Jul, 2030 (7 years from now)
EP3441392A1	SECURA	A Pharmaceutical Composition For Oral Administration	Jul, 2030 (7 years from now)
EP3150609B1	SECURA	Process For Preparing Certain Chemical Entities	Jul, 2030 (7 years from now)
EP2918589B1	SECURA	Adenine Derivative As Pi3K Inhibitor	Jul, 2030 (7 years from now)
EP3441392B1	SECURA	A Pharmaceutical Composition For Oral Administration	Jul, 2030 (7 years from now)
EP2456444B1	SECURA	Adenine Derivative As Pi3K Inhibitor	Jul, 2030 (7 years from now)
EP2456444A4	SECURA	Certain Chemical Entities, Compositions And Methods	Jul, 2030 (7 years from now)
EP2456444A1	SECURA	Adenine Derivative As Pi3K Inhibitor	Jul, 2030 (7 years from now)

Drugs and Companies using DUVELISIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
15MG	CAPSULE;ORAL	Prescription
25MG	CAPSULE;ORAL	Prescription

41. Drug name - CUBICIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456	CUBIST PHARMS LLC	Lipopeptide compositions and related methods	Nov, 2030 (8 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
250MG/VIAL	POWDER;INTRAVENOUS	Discontinued
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

42. Drug name - CYCLOSET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877708	VEROSCIENCE	Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)
US9895422	VEROSCIENCE	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)
US9352025	VEROSCIENCE	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)
US10688155	VEROSCIENCE	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders	Jun, 2030 (7 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Treatment: Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 11 and wherein the effects are as recited in claim 11; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 2 and wherein the effects are as recited in claim 2; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-19 and wherein the effects are as recited in claims 16-19; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 9 and wherein the effects are as recited in claim 9; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 8 and wherein the effects are as recited in claim 8; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 14 and wherein the effects are as recited in claim 14; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wherein the effects are as recited in claims 3-7; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1-5 and wherein the effects are as recited in claims 1-5; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 7 and wherein the effects are as recited in claim 7; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 14-15 and wherein the effects are as recited in claims 14-15; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 9 and wherein the effects are as recited in claim 9; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-18 and wherein the effects are as recited in claims 16-18; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 10 and wherein the effects are as recited in claim 10; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 6 and wherein the effects are as recited in claim 6; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 19 and wherein the effects are as recited in claim 19; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 10; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 19 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 16 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 2 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 30 wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 27 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 17 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 15 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 28 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine meylate and a first-phase insulin secretagogue as recited in claims 1 and 3 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 8 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 5 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 11; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1, 17 and 18 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 13; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 22 wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 24 and wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 29 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 6 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 26 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 4 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 7 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 25 and wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 9; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 23 and wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 56 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 31 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claims 44 and 54; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 50 wherein the effects are as recited in said claims; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 42 and wherein the effects are as recited in claim 42; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 49 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 45 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 34 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 51 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 32 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 38 and wherein the effects are as recited claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 39 and wherein the effects are as recited in claim 26; once daily topical treatment of persistent facial erythema associated with rosacea in adults; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 36 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 48 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 33 wherein the effects are as recited in claims; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 42 and 43 wherein the effects are as recited in claim 42; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 47 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 40 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 57 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 46 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 52 wherein the effects are as recited in said claims

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.8MG BASE	TABLET;ORAL	Prescription

43. Drug name - DEXILANT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173158	TAKEDA PHARMS USA	Methods of treating gastrointestinal disorders independent of the intake of food	Mar, 2030 (7 years from now)
US8173158 (Pediatric)	TAKEDA PHARMS USA	Methods of treating gastrointestinal disorders independent of the intake of food	Sep, 2030 (7 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; healing of all grades of erosive esophagitis (ee) for up to 8 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
30MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription
60MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

44. Drug name - DEXTENZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563027	OCULAR THERAPEUTIX	Drug delivery through hydrogel plugs	Feb, 2030 (7 years from now)
US8409606	OCULAR THERAPEUTIX	Drug delivery through hydrogel plugs	May, 2030 (7 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

Strength	Dosage	Availability
0.4MG	INSERT;OPHTHALMIC	Prescription

45. Drug name - DSUVIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8574189	ACELRX PHARMS	Storage and dispensing devices for administration of oral transmucosal dosage forms	Mar, 2030 (7 years from now)
US10896751	ACELRX PHARMS	Storage and dispensing devices for administration of oral transmucosal dosage forms	Mar, 2030 (7 years from now)
US8202535	ACELRX PHARMS	Small-volume oral transmucosal dosage forms	Oct, 2030 (8 years from now)
US8865743	ACELRX PHARMS	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain	Oct, 2030 (8 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
EQ 0.03MG BASE	TABLET;SUBLINGUAL	Prescription

46. Drug name - EDARBYCLOR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169238	ARBOR PHARMS LLC	Solid pharmaceutical composition	Feb, 2030 (7 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL;12.5MG	TABLET;ORAL	Prescription
EQ 40MG MEDOXOMIL;25MG	TABLET;ORAL	Prescription

47. Drug name - ELLA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159681	LAB HRA PHARMA	Method for on-demand contraception	Apr, 2030 (7 years from now)
US10772897	LAB HRA PHARMA	Method for on-demand contraception	Apr, 2030 (7 years from now)
US9283233	LAB HRA PHARMA	Method for on-demand contraception	Apr, 2030 (7 years from now)
US8512745	LAB HRA PHARMA	Ulipristal acetate tablets	Jun, 2030 (7 years from now)
US8426392	LAB HRA PHARMA	Method for providing emergency contraception	Jun, 2030 (7 years from now)
US8962603	LAB HRA PHARMA	Method for post coital contraception in overweight or obese female subjects using ulipristal acetate	Jun, 2030 (7 years from now)

Drugs and Companies using ULIPRISTAL ACETATE ingredient

Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse; Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food; Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription

48. Drug name - ENTEREG

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946262	CUBIST PHARMS	Methods of preventing and treating gastrointestinal dysfunction	Feb, 2030 (7 years from now)

Drugs and Companies using ALVIMOPAN ingredient

Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
12MG	CAPSULE;ORAL	Prescription

49. Drug name - EPCLUSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9284342	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2030 (7 years from now)
US8618076	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Dec, 2030 (8 years from now)
CN105085592A	GILEAD SCIENCES INC	N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof	May, 2030 (7 years from now)
CN102459299A	GILEAD SCIENCES INC	N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production	May, 2030 (7 years from now)
CN105085592B	GILEAD SCIENCES INC	N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method	May, 2030 (7 years from now)
CN102459299B	GILEAD SCIENCES INC	N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production	May, 2030 (7 years from now)
IN346815B	GILEAD SCIENCES INC	N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production	May, 2030 (7 years from now)
EP2913337A1	GILEAD SCIENCES INC	Process For The Production Of Sofosbuvir	May, 2030 (7 years from now)
EP3321275B1	GILEAD SCIENCES INC	Crystalline Form Of Sofosbuvir	May, 2030 (7 years from now)
EP2432792A1	GILEAD SCIENCES INC	And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester	May, 2030 (7 years from now)
EP2913337B1	GILEAD SCIENCES INC	Process For The Production Of Sofosbuvir	May, 2030 (7 years from now)
EP3321275A1	GILEAD SCIENCES INC	Crystalline Form Of Sofosbuvir	May, 2030 (7 years from now)
EP2432792B1	GILEAD SCIENCES INC	And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester	May, 2030 (7 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: NA

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
150MG;37.5MG/PACKET	PELLETS;ORAL	Prescription
200MG;50MG/PACKET	PELLETS;ORAL	Prescription

50. Drug name - ERLEADA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445507	JANSSEN BIOTECH	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Sep, 2030 (7 years from now)

Drugs and Companies using APALUTAMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription

51. Drug name - ESBRIET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318780	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (7 years from now)
US7910610	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (7 years from now)
US8754109	GENENTECH INC	Pirfenidone therapy and inducers of cytochrome P450	Jan, 2030 (7 years from now)
US8648098	GENENTECH INC	Pirfenidone therapy and inducers of cytochrome P450	Jan, 2030 (7 years from now)
US8013002	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (7 years from now)
US8084475	GENENTECH INC	Pirfenidone therapy and inducers of cytochrome P450	Jan, 2030 (7 years from now)
US7816383	GENENTECH INC	Methods of administering pirfenidone therapy	Jan, 2030 (7 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Administering pirfenidone while avoiding concomitant use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6; discontinuing use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6 and then administering pirfenidone; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Administering pirfenidone while avoiding concomitant administration of a strong inducer of cyp1a2, including cigarette smoke, to avoid reduced pirfenidone efficacy; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer; Administering pirfenidone concurrently with fluvoxamine, the pirfenidone at a dose of about 801 mg/day to reduce drug interactions with fluvoxamine; modifying pirfenidone administration from a dose of about 2400 mg/day downward by about 1600 mg/day while co-administering fluvoxamine to reduce drug interactions with fluvoxamine; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to reduce drug interactions with fluvoxamine

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
267MG	CAPSULE;ORAL	Prescription

52. Drug name - EUCRISA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168614	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Jan, 2030 (7 years from now)
US8168614 (Pediatric)	ANACOR PHARMS INC	Boron-containing small molecules as anti-inflammatory agents	Jul, 2030 (7 years from now)

Drugs and Companies using CRISABOROLE ingredient

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

Strength	Dosage	Availability
2%	OINTMENT;TOPICAL	Prescription

53. Drug name - EVOMELA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020363	ACROTECH	Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same	May, 2030 (7 years from now)
US10864183	ACROTECH	Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same	May, 2030 (7 years from now)
US10940128	ACROTECH	Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same	Jun, 2030 (7 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 50MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

54. Drug name - EXEM FOAM KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300	GISKIT	Composition and method for medical imaging of body cavities	Oct, 2030 (8 years from now)

Drugs and Companies using AIR POLYMER-TYPE A ingredient

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

Strength	Dosage	Availability
10ML	FOAM;INTRAUTERINE	Prescription

55. Drug name - FABIOR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859	MAYNE PHARMA	Topical foam composition	Feb, 2030 (7 years from now)
US10688071	MAYNE PHARMA	Topical foam composition	Feb, 2030 (7 years from now)
US8808716	MAYNE PHARMA	Topical foam composition	Feb, 2030 (7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

Strength	Dosage	Availability
0.1%	AEROSOL, FOAM;TOPICAL	Prescription

56. Drug name - FANAPT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9157121	VANDA PHARMS INC	Method of treatment based on polymorphisms of the KCNQ1 gene	Apr, 2030 (7 years from now)
US8652776	VANDA PHARMS INC	Prediction of QT prolongation based on SNP genotype	Aug, 2030 (7 years from now)
US8999638	VANDA PHARMS INC	Method of treatment based on polymorphisms of the KCNQ1 gene	Oct, 2030 (8 years from now)
US9074255	VANDA PHARMS INC	Method of predicting a predisposition to QT prolongation	Dec, 2030 (8 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

57. Drug name - FARXIGA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8721615	ASTRAZENECA AB	Ampoule comprising an ampoule holder	Jan, 2030 (7 years from now)
US8685934	ASTRAZENECA AB	Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof	May, 2030 (7 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

58. Drug name - FLOLIPID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597289	TCG FLUENT PHARMA	Liquid oral simvastatin compositions	Feb, 2030 (7 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
20MG/5ML	SUSPENSION;ORAL	Prescription
40MG/5ML	SUSPENSION;ORAL	Prescription

59. Drug name - FOSRENOL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023397	TAKEDA PHARMS USA	Capsule and powder formulations containing lanthanum compounds	Dec, 2030 (8 years from now)
US8980327	TAKEDA PHARMS USA	Capsule and powder formulations containing lanthanum compounds	Dec, 2030 (8 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Treatment: NA

Dosage: POWDER;ORAL

Strength	Dosage	Availability
EQ 1GM BASE	POWDER;ORAL	Prescription
EQ 750MG BASE	POWDER;ORAL	Prescription

60. Drug name - FYARRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206887	AADI	Prion free nanoparticle compositions and methods of making thereof	Apr, 2030 (7 years from now)

Drugs and Companies using SIROLIMUS ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

61. Drug name - GEMTESA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8247415	UROVANT	Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists	Dec, 2030 (8 years from now)

Drugs and Companies using VIBEGRON ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription

62. Drug name - GENOSYL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103669	VERO BIOTECH	Nitric oxide therapies	Jun, 2030 (7 years from now)
US8607785	VERO BIOTECH	Systems and devices for generating nitric oxide	Jul, 2030 (7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

Strength	Dosage	Availability
800PPM	GAS;INHALATION	Prescription

63. Drug name - GENVOYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8148374 (Pediatric)	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Mar, 2030 (7 years from now)
US9891239 (Pediatric)	GILEAD SCIENCES INC	Modulators of pharmacokinetic properties of therapeutics	Mar, 2030 (7 years from now)
US8633219	GILEAD SCIENCES INC	Combination therapy	Apr, 2030 (7 years from now)
US8633219 (Pediatric)	GILEAD SCIENCES INC	Combination therapy	Oct, 2030 (8 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;EQ 10MG BASE	TABLET;ORAL	Prescription

64. Drug name - GILOTRIF

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8426586 (Pediatric)	BOEHRINGER INGELHEIM	Process for preparing amino crotonyl compounds	Apr, 2030 (7 years from now)
US8545884 (Pediatric)	BOEHRINGER INGELHEIM	Solid pharmaceutical formulations comprising BIBW 2992	Jun, 2030 (7 years from now)
US10004743	BOEHRINGER INGELHEIM	Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient	Jul, 2030 (7 years from now)

Drugs and Companies using AFATINIB DIMALEATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription

65. Drug name - GIMOTI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334281	EVOKE PHARMA INC	Nasal formulations of metoclopramide	May, 2030 (7 years from now)

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
EQ 15MG BASE/SPRAY	SPRAY, METERED;NASAL	Prescription

66. Drug name - GOCOVRI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741343	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (8 years from now)
US9867792	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (8 years from now)
US9867791	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (8 years from now)
US9877933	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (8 years from now)
US9867793	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (8 years from now)
US11197835	ADAMAS PHARMA	Method of administering amantadine prior to a sleep period	Dec, 2030 (8 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 68.5MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 137MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

67. Drug name - HARVONI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8822430	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8088368	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US9284342	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Sep, 2030 (7 years from now)
US8618076	GILEAD SCIENCES INC	Nucleoside phosphoramidates	Dec, 2030 (8 years from now)
CN104211689B	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN106588890B	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN104211689A	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN104230900B	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN102596936A	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN103977406B	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN104016971A	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN104211713B	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN102596936B	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN104211713A	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
CN106588890A	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN104016971B	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN103977406A	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN104230900A	GILEAD SCIENCES INC	Antiviral Compound	May, 2030 (7 years from now)
CN105085592B	GILEAD SCIENCES INC	N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method	May, 2030 (7 years from now)
CN102459299A	GILEAD SCIENCES INC	N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production	May, 2030 (7 years from now)
CN102459299B	GILEAD SCIENCES INC	N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production	May, 2030 (7 years from now)
CN105085592A	GILEAD SCIENCES INC	N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof	May, 2030 (7 years from now)
IN346815B	GILEAD SCIENCES INC	N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production	May, 2030 (7 years from now)
EP2873665A1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP3309157A1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP2873665B1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP3002281B1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP3309157B1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP3002281A1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP2430014B1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP2430014A1	GILEAD SCIENCES INC	Antiviral Compounds	May, 2030 (7 years from now)
EP2913337A1	GILEAD SCIENCES INC	Process For The Production Of Sofosbuvir	May, 2030 (7 years from now)
EP3321275B1	GILEAD SCIENCES INC	Crystalline Form Of Sofosbuvir	May, 2030 (7 years from now)
EP2432792A1	GILEAD SCIENCES INC	And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester	May, 2030 (7 years from now)
EP2913337B1	GILEAD SCIENCES INC	Process For The Production Of Sofosbuvir	May, 2030 (7 years from now)
EP3321275A1	GILEAD SCIENCES INC	Crystalline Form Of Sofosbuvir	May, 2030 (7 years from now)
EP2432792B1	GILEAD SCIENCES INC	And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester	May, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511056	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8273341	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8841278	GILEAD SCIENCES INC	Antiviral compounds	May, 2030 (7 years from now)
US8822430 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (8 years from now)
US8841278 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (8 years from now)
US9511056 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (8 years from now)
US8088368 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (8 years from now)
US8273341 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	Nov, 2030 (8 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
33.75MG;150MG/PACKET	PELLETS;ORAL	Prescription
45MG;200MG/PACKET	PELLETS;ORAL	Prescription

68. Drug name - IBSRELA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006281	ARDELYX INC	Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders	May, 2030 (7 years from now)

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription

69. Drug name - IDHIFA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125	CELGENE CORP	Methods and compositions for cell-proliferation-related disorders	Jun, 2030 (7 years from now)

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

70. Drug name - ILEVRO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662398	NOVARTIS	Carboxylvinyl polymer-containing nanoparticle suspensions	Dec, 2030 (8 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.3%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

71. Drug name - IMPLANON

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9757552	ORGANON	Applicator for inserting an implant	Jul, 2030 (7 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

Strength	Dosage	Availability
68MG/IMPLANT	IMPLANT;IMPLANTATION	Prescription

72. Drug name - IMPOYZ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10064875	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US9956231	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)
US10588914	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (7 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Treatment: Treatment of moderate plaque psoriasis; treatment of plaque psoriasis; psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of moderate plaque psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; psoriasis; twice daily topical treatment of moderate to severe plaque psoriasis.; treatment of plaque psoriasis; plaque psoriasis; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
0.025%	CREAM;TOPICAL	Prescription

73. Drug name - INCRUSE ELLIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281	GLAXO GRP ENGLAND	Manifold for use in medicament dispenser	Mar, 2030 (7 years from now)
US8746242	GLAXO GRP ENGLAND	Medicament dispenser	Oct, 2030 (8 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
EQ 62.5MCG BASE/INH	POWDER;INHALATION	Prescription

74. Drug name - INLYTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8791140	PF PRISM CV	Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals	Dec, 2030 (8 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

75. Drug name - INQOVI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268800	OTSUKA	Certain compounds, compositions and methods	Aug, 2030 (7 years from now)

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG;35MG	TABLET;ORAL	Prescription

76. Drug name - ISENTRESS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311	MERCK SHARP DOHME	Solid pharmaceutical compositions containing an integrase inhibitor	Oct, 2030 (8 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 600MG BASE	TABLET;ORAL	Prescription

77. Drug name - JATENZO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10617696	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179403	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US8778916	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US10543219	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Apr, 2030 (7 years from now)
US8492369	CLARUS	Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same	Dec, 2030 (8 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
158MG	CAPSULE;ORAL	Prescription
198MG	CAPSULE;ORAL	Prescription
237MG	CAPSULE;ORAL	Prescription

78. Drug name - JENTADUETO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)
US8846695	BOEHRINGER INGELHEIM	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor	Jun, 2030 (7 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET;ORAL	Prescription
2.5MG;500MG	TABLET;ORAL	Prescription
2.5MG;850MG	TABLET;ORAL	Prescription

79. Drug name - JENTADUETO XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705	BOEHRINGER INGELHEIM	DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation	May, 2030 (7 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

80. Drug name - JEVTANA KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583110	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (8 years from now)
US10716777	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (8 years from now)
US8927592	SANOFI AVENTIS US	Antitumoral use of cabazitaxel	Oct, 2030 (8 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
60MG/1.5ML (40MG/ML)	SOLUTION;INTRAVENOUS	Prescription

81. Drug name - JUBLIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10105444	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (7 years from now)
US9861698	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (7 years from now)
US8039494	BAUSCH	Compositions and methods for treating diseases of the nail	Jul, 2030 (7 years from now)
US8486978	BAUSCH	Compositions and methods for treating diseases of the nail	Oct, 2030 (8 years from now)
US9302009	BAUSCH	Compositions and methods for treating diseases of the nail	Oct, 2030 (8 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Antimycotic uses, specifically treatment of onychomycosis

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
10%	SOLUTION;TOPICAL	Prescription

82. Drug name - JYNARQUE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694	OTSUKA	Pharmaceutical solid preparation comprising benzazepines and production method thereof	Apr, 2030 (7 years from now)

Drugs and Companies using TOLVAPTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
15MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
45MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription

83. Drug name - KENGREAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427448	CHIESI	Methods of treating, reducing the incidence of, and/or preventing ischemic events	Nov, 2030 (8 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription

84. Drug name - KIMYRSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061	MELINTA THERAP	Methods of treating bacterial infections using oritavancin	Apr, 2030 (7 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1.2GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

85. Drug name - KISQALI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

86. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980	NOVARTIS	Pyrrolopyrimidine compounds and their uses	May, 2030 (7 years from now)

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG;EQ 200MG BASE	TABLET;ORAL	Prescription

87. Drug name - KOVANAZE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308191	ST RENATUS	Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration	Apr, 2030 (7 years from now)
US8580282	ST RENATUS	Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration	Apr, 2030 (7 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient

Treatment: Method of anesthetizing at least a portion of the maxillary dental arch

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.1MG/SPRAY;6MG/SPRAY	SPRAY, METERED;NASAL	Prescription

88. Drug name - KYBELLA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500214	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US8101593	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US8367649	KYTHERA BIOPHARMS	Formulations of deoxycholic acid and salts thereof	Mar, 2030 (7 years from now)
US8653058	KYTHERA BIOPHARMS	Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits	Mar, 2030 (7 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
20MG/2ML (10MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

89. Drug name - KYNMOBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044475	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9669021	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9669019	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9283219	SUNOVION PHARMS INC	Sublingual films	Jun, 2030 (7 years from now)
US10420763	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)
US9326981	SUNOVION PHARMS INC	Sublingual apomorphine	Jun, 2030 (7 years from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

Strength	Dosage	Availability
10MG	FILM;SUBLINGUAL	Prescription
15MG	FILM;SUBLINGUAL	Prescription
20MG	FILM;SUBLINGUAL	Prescription
25MG	FILM;SUBLINGUAL	Prescription
30MG	FILM;SUBLINGUAL	Prescription

90. Drug name - LONHALA MAGNAIR KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789270	SUNOVION RESP	Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized	Oct, 2030 (8 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

Strength	Dosage	Availability
25MCG/ML	SOLUTION;INHALATION	Prescription

91. Drug name - LUMIFY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259425	BAUSCH AND LOMB INC	Compositions and methods for eye whitening	Jul, 2030 (7 years from now)
US8293742	BAUSCH AND LOMB INC	Preferential vasoconstriction compositions and methods of use	Jul, 2030 (7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.025%	SOLUTION/DROPS;OPHTHALMIC	Over the counter

92. Drug name - MAVYRET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US10039754	ABBVIE INC	Anti-viral compounds	Jun, 2030 (7 years from now)
US9586978	ABBVIE INC	Anti-viral compounds	Nov, 2030 (8 years from now)
US10028937 (Pediatric)	ABBVIE INC	Anti-viral compounds	Dec, 2030 (8 years from now)
US10039754 (Pediatric)	ABBVIE INC	Anti-viral compounds	Dec, 2030 (8 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG;40MG	TABLET;ORAL	Prescription

93. Drug name - MAYZENT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441	NOVARTIS	Dosage regimen of an S1P receptor agonist	Nov, 2030 (8 years from now)

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.25MG BASE	TABLET;ORAL	Prescription
EQ 1MG BASE	TABLET;ORAL	Prescription
EQ 2MG BASE	TABLET;ORAL	Prescription

94. Drug name - MEKINIST

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8703781	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors	Oct, 2030 (8 years from now)
CN102655753B	NOVARTIS	Combined Medicine	Oct, 2030 (8 years from now)
CN102655753A	NOVARTIS	Combination	Oct, 2030 (8 years from now)
EP2488033A1	NOVARTIS	Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor	Oct, 2030 (8 years from now)
EP2488033A4	NOVARTIS	Combination	Oct, 2030 (8 years from now)
EP2488033B1	NOVARTIS	Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor	Oct, 2030 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018	NOVARTIS	Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors	Oct, 2030 (8 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG	TABLET;ORAL	Prescription
EQ 1MG	TABLET;ORAL	Discontinued
EQ 2MG	TABLET;ORAL	Prescription

95. Drug name - MEKTOVI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10005761	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9850229	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)
US9593100	ARRAY BIOPHARMA INC	Compounds and compositions as protein kinase inhibitors	Aug, 2030 (7 years from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
15MG	TABLET;ORAL	Prescription

96. Drug name - MILPROSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580293	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Jan, 2030 (7 years from now)

Drugs and Companies using PROGESTERONE ingredient

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

Strength	Dosage	Availability
1.78GM	SYSTEM;VAGINAL	Discontinued

97. Drug name - MINIVELLE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8231906	NOVEN	Transdermal estrogen device and delivery	Jul, 2030 (7 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Dosage	Availability
0.025MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.0375MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.05MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.075MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

98. Drug name - MULPLETA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8530668	SHIONOGI INC	Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor	Jan, 2030 (7 years from now)

Drugs and Companies using LUSUTROMBOPAG ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription

99. Drug name - MYOVIEW

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549999	GE HEALTHCARE	Radiopharmaceutical composition	Mar, 2030 (7 years from now)

Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
N/A	INJECTABLE;INJECTION	Prescription

100. Drug name - MYRBETRIQ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842780 (Pediatric)	APGDI	Pharmaceutical composition for modified release	Mar, 2030 (7 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
50MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

101. Drug name - NERLYNX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7399865	PUMA BIOTECH	Protein tyrosine kinase enzyme inhibitors	Dec, 2030 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211291	PUMA BIOTECH	Treatment regimen utilizing neratinib for breast cancer	Mar, 2030 (7 years from now)
US8790708	PUMA BIOTECH	Coated tablet formulations and uses thereof	Nov, 2030 (8 years from now)
US8518446	PUMA BIOTECH	Coated tablet formulations and uses thereof	Nov, 2030 (8 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 40MG BASE	TABLET;ORAL	Prescription

102. Drug name - NEUPRO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130589	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Dec, 2030 (8 years from now)
US10350174	UCB INC	Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine	Dec, 2030 (8 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Dosage	Availability
1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
2MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
4MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
8MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

103. Drug name - NOCDURNA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974826	FERRING PHARMS INC	Methods comprising desmopressin	Apr, 2030 (7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
0.0277MG	TABLET;SUBLINGUAL	Prescription
0.0553MG	TABLET;SUBLINGUAL	Prescription

104. Drug name - NOCTIVA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539302	SERENITY PHARMS LLC	Safe desmopressin administration	Jun, 2030 (7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.00083MG/SPRAY	SPRAY, METERED;NASAL	Discontinued
0.00166MG/SPRAY	SPRAY, METERED;NASAL	Discontinued

105. Drug name - NUBEQA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8975254	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (8 years from now)
US10711013	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (8 years from now)
US11046713	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (8 years from now)
US9657003	BAYER HEALTHCARE	Androgen receptor modulating compounds	Oct, 2030 (8 years from now)
CN102596910A	BAYER HEALTHCARE	Androgen Receptor Modulator Compounds	Oct, 2030 (8 years from now)
CN105061313A	BAYER HEALTHCARE	Androgen Receptor Regulation Compound	Oct, 2030 (8 years from now)
CN105061313B	BAYER HEALTHCARE	Androgen Receptor Modulator Compounds	Oct, 2030 (8 years from now)
CN102596910B	BAYER HEALTHCARE	Androgen Receptor Modulator Compounds	Oct, 2030 (8 years from now)
IN304033B	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
IN201200848P2	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
EP3056485B1	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
EP3369732B1	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
EP3369732A1	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
EP3056485A1	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
EP2493858B1	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)
EP2493858A1	BAYER HEALTHCARE	Androgen Receptor Modulating Compounds	Oct, 2030 (8 years from now)

Drugs and Companies using DAROLUTAMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription

106. Drug name - NUPLAZID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601740	ACADIA PHARMS INC	Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases	Apr, 2030 (7 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 17MG BASE	TABLET;ORAL	Discontinued

107. Drug name - NUZYRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8383610	PARATEK PHARMS INC	Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline	Sep, 2030 (7 years from now)

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription

108. Drug name - OLUMIANT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616	ELI LILLY AND CO	Azetidine and cyclobutane derivatives as JAK inhibitors	Jun, 2030 (7 years from now)

Drugs and Companies using BARICITINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription

109. Drug name - ONGENTYS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583130	NEUROCRINE	Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (7 years from now)
US10071085	NEUROCRINE	Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof	Mar, 2030 (7 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription
50MG	CAPSULE;ORAL	Prescription

110. Drug name - ONPATTRO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802644	ALNYLAM PHARMS INC	Lipid formulation	Oct, 2030 (8 years from now)
US8158601	ALNYLAM PHARMS INC	Lipid formulation	Nov, 2030 (8 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

111. Drug name - ONUREG

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628	CELGENE CORP	Oral formulations of cytidine analogs and methods of use thereof	Jun, 2030 (7 years from now)

Drugs and Companies using AZACITIDINE ingredient

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

112. Drug name - ONZETRA XSAIL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8899229	CURRAX	Powder delivery devices	Aug, 2030 (7 years from now)
US9649456	CURRAX	Nasal administration	Oct, 2030 (8 years from now)
US8978647	CURRAX	Nasal delivery	Dec, 2030 (8 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

113. Drug name - ORBACTIV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061	MELINTA THERAP	Methods of treating bacterial infections using oritavancin	Apr, 2030 (7 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 400MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

114. Drug name - ORENITRAM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410169	UNITED THERAP	Compounds and methods for delivery of prostacyclin analogs	Feb, 2030 (7 years from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 0.125MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 0.25MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 1MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

115. Drug name - ORKAMBI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8507534	VERTEX PHARMS INC	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	Sep, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716338	VERTEX PHARMS INC	Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	Sep, 2030 (7 years from now)
US8993600	VERTEX PHARMS INC	Modulators of ATP-binding cassette transporters	Dec, 2030 (8 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor as recited in claim 1 of us patent 8716338 and ivacaftor

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
125MG/PACKET;100MG/PACKET	GRANULE;ORAL	Prescription
188MG/PACKET;150MG/PACKET	GRANULE;ORAL	Prescription

116. Drug name - OSMOLEX ER

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252331	ADAMAS PHARMA	Osmotic device containing amantadine and an osmotic salt	Mar, 2030 (7 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 129MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 161MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 193MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 258MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

117. Drug name - OTIPRIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318817	ALK ABELLO	Controlled release antimicrobial compositions and methods for the treatment of otic disorders	Apr, 2030 (7 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: Treatment of otic infection or inflammation

Dosage: INJECTABLE, SUSPENSION;OTIC

Strength	Dosage	Availability
6% (60MG/ML)	INJECTABLE, SUSPENSION;OTIC	Prescription

118. Drug name - OTOVEL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8932610	LABORATORIOS SALVAT	Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation	Mar, 2030 (7 years from now)

Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient

Treatment: Treatment of acute otitis media

Dosage: SOLUTION/DROPS;OTIC

Strength	Dosage	Availability
EQ 0.3% BASE;0.025%	SOLUTION/DROPS;OTIC	Prescription

119. Drug name - OTREXUP

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421333	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8945063	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8579865	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)
US8480631	OTTER PHARMS	Hazardous agent injection system	Mar, 2030 (7 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
7.5MG/0.4ML (7.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued
10MG/0.4ML (10MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Discontinued
12.5MG/0.4ML (12.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.4ML (15MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
17.5MG/0.4ML (17.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
20MG/0.4ML (20MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
22.5MG/0.4ML (22.5MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
25MG/0.4ML (25MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.6ML (15MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Discontinued
17.5MG/0.7ML (17.5MG/0.7ML)	SOLUTION;SUBCUTANEOUS	Discontinued
20MG/0.8ML (20MG/0.8ML)	SOLUTION;SUBCUTANEOUS	Discontinued
22.5MG/0.9ML (22.5MG/0.9ML)	SOLUTION;SUBCUTANEOUS	Discontinued
25MG/ML (25MG/ML)	SOLUTION;SUBCUTANEOUS	Discontinued

120. Drug name - OXYCONTIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8894987	PURDUE PHARMA LP	Tamper resistant dosage forms	Mar, 2030 (7 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
10MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
60MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
80MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

121. Drug name - PARSABIV

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Jul, 2030 (7 years from now)
US9701712	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Jul, 2030 (7 years from now)
US8377880	KAI PHARMS INC	Therapeutic agents for reducing parathyroid hormone levels	Jul, 2030 (7 years from now)
CN102711789A	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
CN102711789B	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Level	Jul, 2030 (7 years from now)
IN350519B	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
IN201201196P1	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP3192520B1	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP3539555A1	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP3539555B1	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP3192520A1	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP2459208A4	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP2459208B1	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)
EP2459208A2	KAI PHARMS INC	Therapeutic Agents For Reducing Parathyroid Hormone Levels	Jul, 2030 (7 years from now)

Drugs and Companies using ETELCALCETIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION;INTRAVENOUS	Prescription
5MG/ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription
10MG/2ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

122. Drug name - PENNSAID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450	HORIZON	Treatment of pain with topical diclofenac compounds	Aug, 2030 (7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
2%	SOLUTION;TOPICAL	Prescription

123. Drug name - PENNSAID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450	NUVO PHARMS INC	Treatment of pain with topical diclofenac compounds	Aug, 2030 (7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
1.5%	SOLUTION;TOPICAL	Discontinued

124. Drug name - PHOSLYRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8591938	FRESENIUS MEDCL	Liquid compositions of calcium acetate	Feb, 2030 (7 years from now)

Drugs and Companies using CALCIUM ACETATE ingredient

Treatment: Use of phoslyra for reduction of serum phosphorous in patients

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
667MG/5ML	SOLUTION;ORAL	Prescription

125. Drug name - PIQRAY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8227462	NOVARTIS	Pyrrolidine-1,2-dicarboxamide derivatives	Sep, 2030 (7 years from now)

Drugs and Companies using ALPELISIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription

126. Drug name - POMALYST

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993467	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	May, 2030 (7 years from now)
US10555939	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	May, 2030 (7 years from now)
US10555939 (Pediatric)	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Nov, 2030 (8 years from now)
US9993467 (Pediatric)	CELGENE	Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione	Nov, 2030 (8 years from now)

Drugs and Companies using POMALIDOMIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
1MG	CAPSULE;ORAL	Prescription
2MG	CAPSULE;ORAL	Prescription
3MG	CAPSULE;ORAL	Prescription
4MG	CAPSULE;ORAL	Prescription

127. Drug name - PYLARIFY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8778305	PROGENICS PHARMS INC	PSMA-binding agents and uses thereof	Sep, 2030 (7 years from now)

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
50ML (1-80mCi/ML)	SOLUTION;INTRAVENOUS	Prescription

128. Drug name - QBREXZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744105	JOURNEY	Topical glycopyrrolate formulations	Jul, 2030 (7 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

Strength	Dosage	Availability
EQ 2.4% BASE	CLOTH;TOPICAL	Prescription

129. Drug name - QINLOCK

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188113	DECIPHERA PHARMS	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jul, 2030 (7 years from now)

Drugs and Companies using RIPRETINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription

130. Drug name - QMIIZ ODT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879	TERSERA	Fast disintegrating compositions of meloxicam	Aug, 2030 (7 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
7.5MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
15MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

131. Drug name - QTERNMET XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616028	ASTRAZENECA AB	Bilayer tablet formulations	Nov, 2030 (8 years from now)

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM;EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
5MG;1GM;EQ 2.5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
5MG;1GM;EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
10MG;1GM;EQ 5MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

132. Drug name - QUTENZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8821920	AVERITAS	Therapeutic patch for transdermal delivery of capsaicin	Mar, 2030 (7 years from now)

Drugs and Companies using CAPSAICIN ingredient

Treatment: NA

Dosage: PATCH;TOPICAL

Strength	Dosage	Availability
8%	PATCH;TOPICAL	Prescription

133. Drug name - QUZYTTIR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (7 years from now)
US9119771	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (7 years from now)
US8513259	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (7 years from now)
US8314083	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (7 years from now)
US8263581	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (7 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in patients with concomitant angioedema

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
10MG/ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

134. Drug name - RAVICTI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183002	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US10045958	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US10183006	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US10183005	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US10668040	HORIZON THERAP	Treatment of urea cycle disorders in neonates and infants	Sep, 2030 (7 years from now)
US9962359	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US9999608	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US10045959	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US8642012	HORIZON THERAP	Methods of treatment using ammonia-scavenging drugs	Sep, 2030 (7 years from now)
US10183004	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)
US9561197	HORIZON THERAP	Methods of therapeutic monitoring of phenylacetic acid prodrugs	Sep, 2030 (7 years from now)
US10183003	HORIZON THERAP	Methods of therapeutic monitoring of nitrogen scavenging drugs	Sep, 2030 (7 years from now)

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID;ORAL

Strength	Dosage	Availability
1.1GM/ML	LIQUID;ORAL	Prescription

135. Drug name - RELISTOR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247425	SALIX PHARMS	Peripheral opioid receptor antagonists and uses thereof	Dec, 2030 (8 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
8MG/0.4ML (8MG/0.4ML)	SOLUTION;SUBCUTANEOUS	Prescription
12MG/0.6ML (12MG/0.6ML)	SOLUTION;SUBCUTANEOUS	Prescription

136. Drug name - RENVELA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095509	GENZYME	Sachet formulation for amine polymers	Dec, 2030 (8 years from now)

Drugs and Companies using SEVELAMER CARBONATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
2.4GM/PACKET	FOR SUSPENSION;ORAL	Prescription
800MG/PACKET	FOR SUSPENSION;ORAL	Prescription

137. Drug name - RHOPRESSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174017	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (7 years from now)
US10654844	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (7 years from now)
US8394826	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Nov, 2030 (8 years from now)
EP3354643B1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP2424842B1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP2424842A2	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP3354643A1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP3053913B1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP3053913A1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11028081	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (7 years from now)

Drugs and Companies using NETARSUDIL MESYLATE ingredient

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.02% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

138. Drug name - RINVOQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221	ABBVIE INC	Tricyclic compounds	Dec, 2030 (8 years from now)
CN102711476A	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)
CN109053742B	ABBVIE INC	Tricyclic Compounds	Dec, 2030 (8 years from now)
CN104370909A	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)
CN104370909B	ABBVIE INC	Tricyclic Compounds	Dec, 2030 (8 years from now)
CN109053742A	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)
CN102711476B	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)
EP2506716A1	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)
EP2506716B1	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)
EP2506716A4	ABBVIE INC	Novel Tricyclic Compounds	Dec, 2030 (8 years from now)

Drugs and Companies using UPADACITINIB ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

139. Drug name - ROCKLATAN

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174017	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (7 years from now)
US10654844	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (7 years from now)
US8394826	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Nov, 2030 (8 years from now)
EP3354643B1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP2424842B1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP2424842A2	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP3354643A1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP3053913B1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
EP3053913A1	AERIE PHARMS INC	Dual Mechanism Inhibitors For The Treatment Of Disease	Jan, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11028081	AERIE PHARMS INC	Dual mechanism inhibitors for the treatment of disease	Jan, 2030 (7 years from now)

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.005%;EQ 0.02% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

140. Drug name - RYDAPT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8575146	NOVARTIS	Pharmaceutical uses of staurosporine derivatives	Dec, 2030 (8 years from now)

Drugs and Companies using MIDOSTAURIN ingredient

Treatment: Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription

141. Drug name - SAFYRAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597	BAYER HLTHCARE	Pharmaceutical composition containing a tetrahydrofolic acid	Feb, 2030 (7 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	TABLET;ORAL	Prescription

142. Drug name - SALONPAS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809615	HISAMITSU PHARM CO	Adhesive preparation	Jan, 2030 (7 years from now)

Drugs and Companies using MENTHOL; METHYL SALICYLATE ingr

Pharsight

Drug Patents Expiring in 2030

1. Drug name - ABILIFY MYCITE KIT

2. Drug name - ACETAMINOPHEN

3. Drug name - AKYNZEO

4. Drug name - AKYNZEO

5. Drug name - ALECENSA

6. Drug name - ALUNBRIG

7. Drug name - AMONDYS 45

8. Drug name - AMZEEQ

9. Drug name - ANJESO

10. Drug name - ANORO ELLIPTA

11. Drug name - APADAZ

12. Drug name - APRISO

13. Drug name - APTIOM

14. Drug name - ARISTADA

15. Drug name - ARISTADA INITIO KIT

16. Drug name - ARNUITY ELLIPTA

17. Drug name - ATROVENT HFA

18. Drug name - AUBAGIO

19. Drug name - AURYXIA

20. Drug name - AVYCAZ

21. Drug name - BESIVANCE

22. Drug name - BEVESPI AEROSPHERE

23. Drug name - BEVYXXA

24. Drug name - BEYAZ

25. Drug name - BRAFTOVI

26. Drug name - BREO ELLIPTA

27. Drug name - BREXAFEMME

28. Drug name - BREZTRI AEROSPHERE

29. Drug name - BRILINTA

30. Drug name - BRIVIACT

31. Drug name - BYDUREON

32. Drug name - BYDUREON BCISE

33. Drug name - CABOMETYX

34. Drug name - CALDOLOR

35. Drug name - CHILDREN'S ALLEGRA ALLERGY

36. Drug name - COMBIVENT RESPIMAT

37. Drug name - COMETRIQ

38. Drug name - CONSENSI

39. Drug name - CONTRAVE

40. Drug name - COPIKTRA

41. Drug name - CUBICIN

42. Drug name - CYCLOSET

43. Drug name - DEXILANT

44. Drug name - DEXTENZA

45. Drug name - DSUVIA

46. Drug name - EDARBYCLOR

47. Drug name - ELLA

48. Drug name - ENTEREG

49. Drug name - EPCLUSA

50. Drug name - ERLEADA

51. Drug name - ESBRIET

52. Drug name - EUCRISA

53. Drug name - EVOMELA

54. Drug name - EXEM FOAM KIT

55. Drug name - FABIOR

56. Drug name - FANAPT

57. Drug name - FARXIGA

58. Drug name - FLOLIPID

59. Drug name - FOSRENOL

60. Drug name - FYARRO

61. Drug name - GEMTESA

62. Drug name - GENOSYL

63. Drug name - GENVOYA

64. Drug name - GILOTRIF

65. Drug name - GIMOTI

66. Drug name - GOCOVRI

67. Drug name - HARVONI

68. Drug name - IBSRELA

69. Drug name - IDHIFA

70. Drug name - ILEVRO

71. Drug name - IMPLANON

72. Drug name - IMPOYZ

73. Drug name - INCRUSE ELLIPTA

74. Drug name - INLYTA

75. Drug name - INQOVI

76. Drug name - ISENTRESS

77. Drug name - JATENZO

78. Drug name - JENTADUETO